Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$1.88
-5.1%
$2.95
$1.75
$39.38
$14.58M5.55197,528 shs59,916 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
-2.1%
$0.01
$0.01
$0.02
$1.14M-1.01444,201 shs104,378 shs
PTEIQ
PolarityTE
$0.15
$0.05
$0.09
$1.24M0.9227,292 shs313 shs
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$0.07
$0.06
$0.06
$3.23
N/A0.98896,182 shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-17.50%-21.74%-42.11%-42.53%-92.86%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
-4.00%0.00%-3.03%+2.13%-3.03%
PTEIQ
PolarityTE
0.00%0.00%0.00%+13.26%+4.62%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00%0.00%0.00%0.00%-96.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
1.2253 of 5 stars
0.05.00.00.02.81.70.0
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.5728 of 5 stars
0.03.00.04.80.00.00.0
PTEIQ
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00
N/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
PTEIQ
PolarityTE
0.00
N/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K23.86N/AN/A$0.50 per share3.76
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
PTEIQ
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$730K0.40N/AN/A$4.04 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$44.54M-$8.31N/AN/A-7,652.75%N/A-285.71%8/11/2025 (Estimated)
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
PTEIQ
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
-$21.24M-$6.44N/AN/A-1,596.64%-310.17%-196.06%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
PTEIQ
PolarityTE
N/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
0.21
0.21
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
PTEIQ
PolarityTE
N/A
4.11
4.11
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/A
0.89
0.89

Institutional Ownership

CompanyInstitutional Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
PTEIQ
PolarityTE
11.75%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
15.25%

Insider Ownership

CompanyInsider Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
1.50%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
PTEIQ
PolarityTE
5.40%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
107.36 million7.26 millionNo Data
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
PTEIQ
PolarityTE
607.32 million6.99 millionNot Optionable
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
194.44 million4.24 millionOptionable

Recent News About These Companies

TFF Pharmaceuticals approves dissolution plan
The TFFP Stock Mystery: Why Did TFFP Plunge Today?
TFF Pharmaceuticals Shares Fall 66%; Company to Wind Down
TFF Pharmaceuticals terminates employees, to wind down operations
TFF Pharmaceuticals to Dissolve and Liquidate Assets
TFF Pharmaceuticals Announces It Will Wind Down Operations
Post-COVID Trends in Biopharma Contract Manufacturing
The Yadot Group to Acquire Experiential Agency Socials Dallas

Media Sentiment Over Time

Top Headlines

View All Headlines
Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$1.88 -0.10 (-5.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.91 +0.03 (+1.60%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0094 0.00 (-2.08%)
As of 03:50 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

PolarityTE NASDAQ:PTEIQ

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

TFF Pharmaceuticals stock logo

TFF Pharmaceuticals NASDAQ:TFFP

$0.06 0.00 (0.00%)
As of 04/10/2025

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.